Kuros Biosciences

If CHF 10,000 had been invested in Kuros Biosciences a year ago (closing price then 26.58 CHF), that would equal 376.223 shares at the last closing price of 23.00 CHF, worth CHF 8,653.12 today. That corresponds to a decline of 13.47 percent. Market capitalization most recently stood at CHF 914.34 million; calculation does not take stock splits or dividends into account. » Más en finanzen.net

Kuros reports a strong H1 2026: revenue rose 45% to $92.4 million and adjusted EBITDA increased 61% to $12.5 million, with the margin improving to 13.6%. The company posted a first-time net profit of $4.4 million after a loss in the prior year. Kuros reiterates its full-year targets of at least 35% revenue growth and an adjusted EBITDA margin of around 14%, and it confirms its mid-term 2028 target (revenue $300–330 million, adjusted EBITDA margin ≥20%). To support growth, Kuros is advancing product development, market expansion and production capacity in the US and the Netherlands. » Más en finanzen.net

Three years ago the Kuros (Kuros Biosciences) stock traded at 2.09 CHF. A 10,000 CHF investment would be worth 97,607.66 CHF today at a closing price of 20.40 CHF, an increase of 876.08%. Market capitalization most recently stood at 786.78 million CHF; stock splits and dividends were not included in the calculation. » Más en finanzen.net